Management of Constipation in CREST Syndrome
Start with dietary modifications (adequate fiber and fluid intake) combined with osmotic laxatives, specifically macrogols (polyethylene glycol), as first-line therapy, then escalate to stimulant laxatives if needed, and consider prucalopride for refractory cases given its specific evidence in systemic sclerosis patients. 1
Stepwise Treatment Algorithm
Step 1: Dietary and Lifestyle Modifications
Begin by ensuring adequate fiber (unprocessed wheat bran or oat bran with food/juice) and fluid intake. If bran is not tolerated, use methylcellulose, ispaghula, or sterculia as bulk-forming alternatives. 1
Step 2: Osmotic Laxatives (First-Line Pharmacotherapy)
Macrogols (polyethylene glycol) are the preferred osmotic laxative as they sequester fluid in the bowel without causing electrolyte disturbances. 1 Alternative osmotic agents include:
- Lactulose (semi-synthetic disaccharide that produces osmotic effect)
- Magnesium salts for rapid evacuation when needed
- Avoid sodium salts as they cause sodium and water retention 1
Step 3: Add Stimulant Laxatives
If osmotic laxatives provide inadequate response, add stimulant laxatives such as:
- Senna (anthraquinone laxative acting on descending/sigmoid colon)
- Bisacodyl 10-15 mg daily to three times daily
- Sodium picosulfate
- Docusate sodium (combined stimulant/softening effect)
Important caveat: Avoid stimulant laxatives if intestinal obstruction is suspected, and be aware they can cause abdominal cramping, diarrhea, and hypokalemia with excessive use. 1
Step 4: Prokinetic Agents for Refractory Cases
Prucalopride is specifically supported for systemic sclerosis patients with constipation. A 2025 EULAR systematic review found that prucalopride (a selective 5-HT4 receptor agonist) significantly improved colonic function, intestinal evacuations, UCLA GIT 2.0 constipation scores, and orofecal transit time in SSc patients with mild-to-severe constipation. 2 It also reduced GERD severity as a secondary benefit. Seven subjects withdrew due to side effects, so monitoring is essential.
Prucalopride is licensed for chronic constipation when other laxatives fail, with headache and GI symptoms (abdominal pain, nausea, diarrhea) being the most common but generally transient side effects. 1
Step 5: Alternative Prokinetic Options
If prucalopride is unavailable or not tolerated:
- Octreotide (50-100 μg subcutaneously once or twice daily) may be dramatically beneficial especially in systemic sclerosis when other treatments have failed. Effects appear within 48 hours and can be maintained for over 2 years. It may be more effective when combined with erythromycin. 1
- Pyridostigmine (parasympathomimetic) has shown benefit for refractory constipation using a stepped dosing regimen, though cardiovascular side effects (severe bradycardia) require caution. 1
Step 6: Secretagogues for Persistent Symptoms
Linaclotide (guanylate cyclase-C agonist) stimulates intestinal chloride secretion, increasing luminal fluid and accelerating transit. 1 This can be considered when standard laxatives and prokinetics are insufficient.
Critical Considerations for CREST Syndrome Patients
Rule out mechanical obstruction before escalating therapy, as stimulant laxatives are contraindicated in obstruction. Physical exam and abdominal imaging may be needed if symptoms suggest obstruction. 1
Assess for impaction, particularly if diarrhea accompanies constipation (overflow around impaction). If impacted, use glycerine suppositories or perform manual disimpaction following premedication with analgesics ± anxiolytics. 3
Evaluate esophageal dysmotility contribution, as CREST patients often have concurrent GERD and esophageal involvement that may worsen constipation symptoms. The 2025 EULAR review noted that domperidone with alginic acid improved GERD symptoms in SSc patients, though 17% did not respond. 2
Common Pitfalls to Avoid
- Don't use sodium-containing laxatives in systemic sclerosis patients due to risk of fluid retention
- Don't assume fiber supplementation alone will suffice in SSc-related dysmotility—these patients typically need pharmacologic intervention
- Don't overlook the need for prokinetics in SSc patients, as their constipation often stems from intestinal dysmotility rather than simple colonic inertia
- Don't delay escalation if initial therapies fail—SSc patients may require more aggressive management than typical functional constipation
The evidence strongly supports a graduated approach starting with osmotic laxatives, but recognizes that CREST/systemic sclerosis patients often require prokinetic therapy due to underlying intestinal dysmotility. Prucalopride has the most specific evidence in this population. 2